+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are studying patients with non-metastatic stage II colon cancer who are part of the Dutch ColoRectal Cancer cohort PLCRC and who consented to additional blood samples. The study aims to evaluate how many patients with detectable circulating tumor DNA ctDNA after surgery begin adjuvant chemotherapy. This observational and interventional trial includes patients who do not have a standard indication for chemotherapy and involves a randomized design to compare ctDNA-guided treatment with standard care. Patients are randomly assigned to one of two groups the ctDNA-based treatment group or the standard care group. In the ctDNA group, blood samples taken after surgery are analyzed for ctDNA. Those with detectable ctDNA are offered 3 months of adjuvant chemotherapy using CAPOX a combination of fluoropyrimidine and oxaliplatin. Patients without detectable ctDNA receive routine follow-up care. The standard care group receives routine follow-up without knowledge of their ctDNA results. Participants will have blood collected before surgery, after surgery, and during follow-up. Researchers will monitor who starts chemotherapy within 8 to 12 weeks after surgery and will track recurrence rates, disease-free survival, overall survival, time to recurrence, quality of life, and cost-effectiveness over several years. Follow-up assessments occur up to 10 years, allowing detailed long-term evaluation of treatment impact and patient outcomes.

Age: 18Years +All GendersPhase Not Applicable
29 locations
C

Actively Recruiting

The trial investigates treatments for patients with high-risk locally advanced rectal cancer. It compares triplet induction chemotherapy FOLFOXIRI with doublet induction chemotherapy CAPOXFOLFOX, both followed by chemoradiotherapy and then either surgery or a watch-and-wait approach. The study aims to find out if the triplet therapy leads to higher complete response rates, better quality of life, and improved long-term outcomes despite a potential increase in side effects. Participants in one group receive FOLFOXIRI chemotherapy given in cycles every two weeks, followed by chemoradiotherapy that includes radiation combined with capecitabine or an alternative drug if needed. The other group receives CAPOX or FOLFOX chemotherapy followed by the same chemoradiotherapy regimen. After these treatments, patients either have surgery or enter a watch-and-wait follow-up if their cancer shows complete response. Imaging scans are done at multiple points to evaluate treatment response, and surgery timing depends on these results. During the study, participants undergo regular imaging with MRI and CT scans, endoscopies, and clinical exams to assess tumor response. Quality of life and work productivity questionnaires are completed at baseline and after treatments. Researchers monitor treatment toxicity, dose adjustments, surgical outcomes, and long-term survival and recurrence over several years. Follow-up includes close monitoring for tumor regrowth or recurrence, especially for those in the watch-and-wait group, with visits scheduled up to five years after treatment.

Age: 18Years +All GendersPhase 3
20 locations
P

Actively Recruiting

Researchers are investigating how various factors beyond tumor stage, such as biochemical, histopathological, genomic, environmental, and clinical characteristics, affect the outcomes of patients diagnosed with colorectal cancer CRC, small bowel cancer, and anal cancer. This observational study aims to collect detailed information from diagnosis through long-term follow-up to better understand prognosis and treatment effects in both early and late-stage cancers. The study addresses the gap between clinical trial populations and real-world patients by including a broader patient group treated in general practice. Participants will be followed prospectively from their initial diagnosis until death. Data collection includes medical history, clinical parameters, imaging, pathology, tumor details, treatments, hospital stays, interventions, and adverse events. With separate consent, patient-reported quality of life and work ability information will also be gathered. Additionally, biological samples obtained during routine care may be collected for further observational and molecular research. This cohort serves as a platform for evaluating new interventions through a Trials within Cohorts TwiCs design. Throughout up to ten years of follow-up, participants will undergo assessments of progression-free survival, disease-free survival, overall survival, and serious adverse events. Quality of life and work ability are assessed at intervals of 3, 6, 12, 24, 36, and 48 months. This extensive data collection supports a wide range of research aims including prognostic studies, molecular analyses, comparisons of new treatments, and health policy evaluations. The study provides a comprehensive view of treatment outcomes and patient experiences in everyday clinical settings.

Age: 18Years +All Genders
70 locations